Market Place
Sourcing Support
All News #Library
Rare Diseases
Palvella Continued Progress: 2 Posters at 2026 AAD Annual Meeting
27 Mar 2026 //
GLOBENEWSWIRE
Palvella Strengthen Team with Appoints of Rare Disease Commercial
23 Mar 2026 //
GLOBENEWSWIRE
Palvella Pharma Secures European Patent For Rapamycin
16 Mar 2026 //
GLOBENEWSWIRE
Palvella Therapeutics Announces Positive SELVA Results for QTORIN
24 Feb 2026 //
GLOBENEWSWIRE
Palvella Hosts SELVA Call on QTORIN for Lymphatic Malformations
23 Feb 2026 //
GLOBENEWSWIRE
Palvella Pharma Reveals Real-World Statin Evidence Gaps
02 Feb 2026 //
GLOBENEWSWIRE
Palvella Therapeutics Provides 2026 Outlook for Rare Skin Disease
09 Jan 2026 //
GLOBENEWSWIRE
FDA Fast-Tracks Palvella`s QTORIN for Angiokeratomas
16 Dec 2025 //
GLOBENEWSWIRE
Palvella Unveils Qtorin Pitavastatin For DSAP Treatment
05 Nov 2025 //
GLOBENEWSWIRE
Fda Awards Year Two Grant for Palvella`s Qtorin Phase 3 Trial
13 Oct 2025 //
GLOBENEWSWIRE
Palvella Therapeutics Expands Qtorin™ Rapamycin Development
24 Sep 2025 //
GLOBENEWSWIRE
Palvella Highlights Advances in Venous Malformations, Rapamycin
17 Sep 2025 //
GLOBENEWSWIRE
Palvella Completes Phase 2 TOIVA Trial Enrollment for QTORIN™
15 Sep 2025 //
GLOBENEWSWIRE
Palvella Therapeutics gets FDA grant for Qtorin trial
09 Jun 2025 //
GLOBENEWSWIRE
Palvella Therapeutics Reports 2024 Financial Results and Update
31 Mar 2025 //
GLOBENEWSWIRE
Palvella Expands Ph 3 Trial For Microcystic Lymphatic Malformations
10 Feb 2025 //
GLOBENEWSWIRE
Palvella Announces Presentations At PeDRA Annual Conference
15 Oct 2024 //
GLOBENEWSWIRE
Palvella`s Commences Ph3 Portion of Phase 2/3 Pivotal Study of PTX-022
13 Nov 2019 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.